Some sore knees can wait, while others need care today

Returning soreness can wait for a routine visit

A regular appointment fits a knee that aches after walking or stiffens after sitting. It also suits swelling that comes and goes without fever. You may want to note what brings the soreness and how long it stays.

A member of the medical team can watch you walk, feel the joint, and check its bend. An X-ray may help when the exam calls for one. You'll then talk about exercise, braces, medicine, shots, or surgery.

You won't need to arrive with an answer.

Fever with a red, warm knee needs care today

Please seek prompt care if you feel feverish and the knee becomes warm, very swollen, or deeply red. An infection can damage the joint quickly. After a recent procedure, severe soreness, fluid leaking from a wound, or spreading redness also needs urgent review.

Calf warmth, redness, or swelling may mean a blood clot after surgery or long travel. If the foot becomes cold or pale, or you notice numbness or trouble lifting it, a routine visit isn't enough.

These symptoms need urgent medical care.

A hard injury needs an exam in person

Get urgent help after an injury if you can't stand on the leg or the joint looks out of line. Fast swelling, a knee that gave way fully, or a joint that locks also calls for an exam. An X-ray or other care may be needed.

Until you're seen, try not to test the knee again and again. You may rest it, support it, and use a cold pack if that feels comfortable. Local urgent care can help when you're unsure how quickly to go.

Safety comes first.

A calm clinic visit is for steady soreness

For a regular visit, write down your medicines and bring an old X-ray report if you have one. Tell the medical team whether walking or sleep has changed. A short account of the home care you've tried can keep the talk focused.

Once urgent problems are ruled out, QC Kinetix offers natural pain treatments: medical providers examine the knee, then prepare your blood or marrow, soft tissue taken from the back of the hip, for use inside the joint at the clinic.

Sources

1. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.'

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. FDA states verbatim: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production. There are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

3. In a randomized trial of 100 patients with moderate-to-severe knee OA eligible for total knee replacement, TKR followed by 12 weeks of non-surgical care improved the KOOS4 score more than the same non-surgical programme alone (32.5 vs 16.0 points; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) — but produced four times as many serious adverse events (24 vs 6, P=0.005), and 26% of the non-surgical group had chosen surgery within 12 months, meaning roughly three-quarters had not.

   Skou ST, Roos EM, Laursen MB, et al. — A Randomized, Controlled Trial of Total Knee Replacement.. New England Journal of Medicine, 2015. DOI: 10.1056/NEJMoa1505467.

4. The IDEA trial randomized 454 overweight and obese adults aged 55+ with painful radiographic knee OA to intensive diet plus exercise, diet alone, or exercise alone for 18 months. Mean weight loss was 10.6 kg (11.4%) with diet+exercise, 8.9 kg (9.5%) with diet, and 1.8 kg (2.0%) with exercise; diet participants had lower knee compressive forces than exercise participants, and the combined group did best on pain and function.

   Messier SP, Mihalko SL, Legault C, et al. — Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial.. JAMA, 2013. DOI: 10.1001/jama.2013.277669.

5. In the 68-week STEP 9 trial, 407 participants with obesity (mean BMI 40.3) and moderate knee OA with at least moderate pain were randomized 2:1 to once-weekly semaglutide 2.4 mg or placebo alongside diet and activity counselling. Weight change was -13.7% vs -3.2%, and WOMAC pain improved -41.7 vs -27.5 points (both P<0.001). Gastrointestinal adverse events drove discontinuation in 6.7% vs 3.0%.

   Bliddal H, Bays H, Czernichow S, et al. — Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.. New England Journal of Medicine, 2024. DOI: 10.1056/NEJMoa2403664.

6. The METEOR trial randomized 351 symptomatic patients aged 45+ with a meniscal tear AND mild-to-moderate knee OA to arthroscopic partial meniscectomy plus physical therapy or to standardized physical therapy alone. At 6 months the WOMAC physical-function improvement was 20.9 vs 18.5 points — a non-significant 2.4-point difference (95% CI -1.8 to 6.5) — and results at 12 months were similar. 30% of the physical-therapy group crossed over to surgery, meaning 70% did not.

   Katz JN, Brophy RH, Chaisson CE, et al. — Surgery versus physical therapy for a meniscal tear and osteoarthritis.. New England Journal of Medicine, 2013. DOI: 10.1056/NEJMoa1301408.